CDKN2A and cancer: To reliably identify HPV-positive cancers with active viral oncoproteins, HPV status is determined by a combination of viral DNA-PCR testing and p16INK4a immunohistochemistry because p16INK4a is the established surrogate marker for HPV-driven transformation [9,10,11].